Your industry news - first Number 1 for Recruitment
We strongly recommend viewing Cleanzine full size in your web browser. Click our masthead above to visit our website version.
Not 'cruising for a bruising' thanks to Lonza!
The need for disinfectants was underscored yet again this Winter, as hundreds of people aboard several cruise ships in the Caribbean fell ill with Norovirus. Lonza - founded in the Swiss Alps in 1897 - tells us its hygiene and preservation business can help combat the spread of Norovirus, with its highly effective Lonzagard family of disinfectants that are offered in multiple delivery forms.
"Reports of the severe gastrointestinal illnesses caused by the Norovirus have plagued the cruise-ship industry for many years," says Ernesto Lippert, Global Director for Lonza's Hygiene & Preservation business. "All too routine are news videos of vessels affected by the outbreaks having to return early to port."
Lonza's line of Lonzagard disinfectant products (available in North America and Europe) facilitates effective cleaning and disinfecting of all areas of a ship, including guest rooms, dining areas, bathrooms and other quarters. These products are offered in multiple, easy-to-use forms, from single-use wipes to sprays and concentrates.
"Our products have proven efficacy against Norovirus and are quick and easy to use; in fact, our North American Wipes Plus 2 offering has a low four-minute contact time," explains Ernesto.
Lonza provides these technologies through partners servicing the cruise ship industry.
The group's hygiene and preservation business offers the broadest portfolio of registered actives, preservatives and formulations for use in disinfectants, sanitisers and institutional and household cleaning products. This wide range of solutions is used to disinfect and sanitise schools, food processing plants, restaurants, grocery stores, hospitals, homes and more.
Lonza has more than 40 major manufacturing and R & D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organised into two market-focused segments: Pharma&Biotech and Specialty Ingredients.
27th March 2014